Theranostic nanoparticles based on bioreducible polyethylenimine-coated iron oxide for reduction-responsive gene delivery and magnetic resonance imaging

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3347-3361

  Li, Dan ^a   Tang, Xin ^b   Pulli, Benjamin ^a   Lin, Chao ^b   Zhao, Peng ^b   Cheng, Jian ^b   Lv, Zhongwei ^a   Yuan, Xueyu ^a   Luo, Qiong ^a   Cai, Haidong ^a   Ye, Meng ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Disulfide; hTERT; MR imaging; Nanoparticles; RNA interference; SSPEI; Tumor

Indexed keywords

CELL DNA; DISULFIDE; DISULFIDE CONTAINING POLYETHYLENEIMINE SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; DITHIOTHREITOL; NANOPARTICLE; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; MAGNETITE NANOPARTICLE; POLYETHYLENEIMINE; TELOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOCHEMICAL COMPOSITION; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; GENE SILENCING; GENETIC TRANSFECTION; HEPG2 CELL LINE; IN VITRO STUDY; MAGNETISM; MALE; MATERIAL COATING; MOUSE; NANOANALYSIS; NANOCHEMISTRY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHYSICAL CHEMISTRY; SURFACE CHARGE; TELOMERASE REVERSE TRANSCRIPTASE GENE; ZETA POTENTIAL; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PROCEDURES;

ANIMALS; CELL SURVIVAL; DISULFIDES; HEP G2 CELLS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE; MICE, NUDE; POLYETHYLENEIMINE; RNA, SMALL INTERFERING; TELOMERASE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904298722     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S61463     Document Type: Article

References (49)

1. Anderson WF. Human gene therapy. Nature. 1998;392:25-30.
2. Luten J, van Nostrum CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Controlled Release. 2008;126(2):97-110.
3. Li S, Huang L. Non-viral gene therapy: promises and challenges. Gene Ther. 2000;7:31-34.
4. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005;4(7): 589-593.
5. Patnaik S, Gupta KC. Novel polyethylenimine-derived nanoparticles for in vivo gene delivery. Expert Opin Drug Deliv. 2013;10(2):215-228.
6. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Delivy Rev. 2003;55(3): 329-347.
7. Jones CH, Chen CK, Ravikrishnan A, Rane S, Pfeifer BA. Overcoming nonviral gene delivery barriers: perspective and future. Mol Pharm. 2013;10(11):4082-4098.
8. Ghilardi A, Pezzoli D, Bellucci MC, et al. Synthesis of multifunctional PAMAM-aminoglycoside conjugates with enhanced transfection efficiency. Bioconjug Chem. 2013;24(11):1928-1936.
9. Boussif O, Lezoualc'H F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo polyethylenimine. Proc Natl Acad Sci U S A. 1995;92(16): 7297-7301.
10. Cheng R, Feng F, Meng FH, Deng C, Feijen J, Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Controlled Release. 2011;152(1):2-12.
11. Son S, Namgung R, Kim J, Singha K, Kim WJ. Bioreducible polymers for gene silencing and delivery. Acc Chem Res. 2012;45(7): 1100-1112.
12. Zhang GY, Liu J, Yang Q, Zhuo R, Jiang X. Disulfide-containing brushed polyethylenimine derivative synthesized by click chemistry for nonviral gene delivery. Bioconjug Chem. 2012;23(6): 1290-1299.
13. Xia W, Wang P, Lin C, et al. Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo. J Control Release. 2012;157(3): 427-436.
14. Xia W, Li Y, Lou B, Wang PJ, Gao XL, Lin C. Bioreducible PEI-siRNA nanocomplex for liver cancer therapy: transfection, biodistribution, and tumor growth inhibition in vivo. J Nanomater. 2013:ID 384717.
15. Shi Y, Zhou L, Wang R, et al. In situ preparation of magnetic nonviral gene vectors and magnetofection in vitro. Nanotechnology. 2010; 21(11):115103.
16. Veiseh O, Kievit FM, Liu V, et al. In vivo safety evaluation of polyarginine coated magnetic nanovectors. Mol Pharm. 2013;10(11):4099-4106.
17. Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials. 2010;31(24): 6317-6324.
18. Kievit FM, Veiseh O, Bhattarai N, et al. PEI-PEG-Chitosan Copolymer Coated Iron Oxide Nanoparticles for Safe Gene Delivery: synthesis, complexation, and transfection. Adv Funct Mater. 2009;19(14): 2244-2251.
19. Chen Y, Wang W, Lian G, et al. Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer. Int J Nanomedicine. 2012;7:359-368.
20. Wang C, Ravi S, Garapati US, et al. Multifunctional chitosan magneticgraphene (CMG) nanoparticles: a theranostic platform for tumortargeted co-delivery of drugs, genes and MRI contrast agents. J Mater Chem B. 2013;1(35):4396-4405.
21. Wan Q, Xie L, Gao L, et al. Self-assembled magnetic theranostic nanoparticles for highly sensitive MRI of minicircle DNA delivery. Nanoscale. 2013;5(2):744-752.
22. Yang X, Hong H, Grailer JJ, et al. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials. 2011;32(17):4151-4160.
23. Yang X, Grailer JJ, Rowland IJ, et al. Multifunctional SPIO/DOX-loaded wormlike polymer vesicles for cancer therapy and MR imaging. Biomaterials. 2010;31(34):9065-9073.
24. Yang X, Pilla S, Grailer JJ, et al. Tumor-targeting, superparamagnetic polymeric vesicles as highly efficient MRI contrast probes. J Mater Chem. 2009;19(32):5812-5817.
25. Ge J, Hu Y, Biasini M, et al. One-step synthesis of highly water soluble magnetite colloidal nanocrystals. Chemistry. 2007;13(25): 7153-7161.
26. Lin C, Ge J. Multifunctional polyethylenimine-conjugated super-paramagnetic nanoparticles for drug delivery and imaging. J Control Release. 2011;152 Suppl 1:e58-e60.
27. Lin C, Engbersen JFJ. PEGylated bioreducible poly(amido amine)s for non-viral gene delivery. Mater Sci Eng C. 2011;31(7):1330-1337.
28. Lin C, Zhao P, Li F, Guo F, Li Z, Wen X. Thermosensitive in situ-forming dextran-pluronic hydrogels through Michael addition. Mater Sci Eng C. 2010;30(8):1236-1244.
29. Lin C, Zhong Z, Lok MC, et al. Novel bioreducible poly(amido amine)s for highly efficient gene delivery. Bioconjug Chem. 2007;18: 138-145.
30. Lin C, Blaauboer CJ, Timoneda MM, et al. Bioreducible poly(amido amine)s with oligoamine side chains: synthesis, characterization, and structural effect on gene delivery. J Control Release. 2008;126(2): 166-174.
31. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage poly(ethylenimine)-mediated cytotoxicity: Implications for gene transfer/therapy. Mol Ther. 2005;11(6): 990-995.
32. Hua MY, Yang HW, Liu H-L, et al. Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy. Biomaterials. 2011;32(34):8999-9010.
33. Pan B, Cui D, Sheng Y, et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 2007; 67(17):8156-8163.
34. Schaffer DV, Fidelman NA, Dan N, Lauffenburger DA. Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery. Biotechnol Bioeng. 2000;67(5):598-606.
35. Xia W, Lin C. Bioreducible polymer-delivered siRNA targeting human telomerase reverse transcriptase for human cancer gene therapy. Ther Deliv. 2012;3(4):439-442.
36. Morin GB. The human telomerase terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59(3): 521-529.
37. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet. 2001;10(7):677-685.
38. Philippi C, Loretz B, Schaefer UF, Lehr CM. Telomerase as an emerging target to fight cancer-opportunities and challenges for nanomedicine. J Control Release. 2010;146(2):228-240.
39. Liu X, Huang H, Wang J, et al. Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol. 2011;82(1):17-23.
40. Gandellini P, Folini M, Bandiera R, et al. Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol. 2007;73(11):1703-1714.
41. Dong X, Liu A, Zer C, et al. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells. BMC Cancer. 2009;9:133.
42. Sharma GG, Gupta A, Wang H, et al. HTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene. 2003;22(1):131-146.
43. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004; 22(3):326-330.
44. Wang LQ, Mu FY. A Web-based design center for vector-based siRNA and siRNA cassette. Bioinformatics. 2004;20(11):1818-1820.
45. Plank C, Mechtler K, Szoka FC, Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther. 1996;7(12):1437-1446.
46. Han HS, Lee J, Kim HR, et al. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo. J Control Release. 2013;168(2): 105-114.
47. El-Dakdouki MH, El-Boubbou K, Zhu DC, Huang X. A simple method for the synthesis of hyaluronic acid coated magnetic nanoparticles for highly efficient cell labelling and in vivo imaging. RSC Adv. 2011;1(8): 1449-1452.
48. Kamat M, El-Boubbou K, Zhu DC, et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug Chem. 2010;21(11):2128-2135.
49. Lin C, Song YY, Lou B, Zhao P. Dextranation of bioreducible cationic polyamide for systemic gene delivery. Biomed Mater Eng. 2014;24(1): 673-682.